

Segment Reporting

by business segment

in million €	Fresenius Medical Care			Fresenius Kabi		
	2008	2007	Change	2008	2007	Change
Sales	7,213	7,093	2 %	2,495	2,030	23 %
thereof contribution to consolidated sales	7,209	7,089	2 %	2,458	1,986	24 %
thereof intercompany sales	4	4	0 %	37	44	-16 %
contribution to consolidated sales	59 %	62 %		20 %	18 %	
EBITDA	1,419	1,418	0 %	544	408	33 %
Depreciation and amortization	282	265	6 %	101	76	33 %
EBIT	1,137	1,153	-1 %	443	332	33 %
Net interest	-229	-271	15 %	-145	-49	-196 %
Net income	556	523	6 %	200	183	9 %
Operating cash flow	691	875	-21 %	205	179	15 %
Cash flow before acquisitions and dividends	233	479	-51 %	83	67	24 %
Total assets	10,720	9,626	11 %	6,240	2,310	170 %
Debt	4,123	3,833	8 %	4,288	1,121	--
Capital expenditure	467	418	12 %	137	116	18 %
Acquisitions	220	262	-16 %	3,612	178	--
Research and development expenses	55	49	12 %	109	86	27 %
Employees (per capita on balance sheet date)	68,050	64,662	5 %	20,457	16,964	21 %
Key figures						
EBITDA margin	19.7 %	20.0 %		21.8 %	20.1 %	
EBIT margin	15.8 %	16.3 %		17.8 %	16.4 %	
Depreciation and amortization in % of sales	3.9 %	3.7 %		4.0 %	3.7 %	
Operating cash flow in % of sales	9.6 %	12.3 %		8.2 %	8.8 %	
ROOA	12.3 %	12.5 %		8.9 % ²⁾	17.7 %	

¹⁾ Prior year's segment data have been adjusted according to the new company structure as of January 1, 2008.

²⁾ The underlying pro-forma EBIT does not include special items from the acquisition of APP Pharmaceuticals, Inc. (APP).

³⁾ including special items from the APP acquisition

⁴⁾ before special items from the APP acquisition